High-avidity T cells are preferentially tolerized in the tumor microenvironment - Wikidata - wikimedia - TriplyDB

High-avidity T cells are preferentially tolerized in the tumor microenvironment

High-avidity T cells are preferentially tolerized in the tumor microenvironment

http://www.wikidata.org/entity/Q34463820

about

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.T cell avidity and tumor immunity: problems and solutions Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT).FOXO3-NF-κB RelA Protein Complexes Reduce Proinflammatory Cell Signaling and Function Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.Spontaneous presence of FOXO3-specific T cells in cancer patients.Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms.Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.The inhibition effect of starch nanoparticles on tyrosinase activity and its mechanism.Frequent adaptive immune responses against arginase-1.Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

P2860

Q26774669-3E2CC96E-2A77-44D6-9366-F398FD6D1302 Q27008423-286BDA1B-40CB-44AE-941D-B8AC048C50B1 Q33679779-4181CCAF-BB5B-4E61-9A8E-429454FF9B82 Q34115960-4879E719-3601-469F-92DD-580635A85C98 Q34240499-E7C8E6C7-CF0C-41C1-A74D-818C1D51D8E9 Q35691240-424BF7E1-9D0F-4C89-9631-ADFC756AEC87 Q36282747-ECBAB93D-3522-4F3A-9A6B-11A4E577B11F Q36349658-11DA82AD-1EAA-4E07-888E-323FA1411DCF Q36813010-BBFEA7EC-B9C3-4503-AD0F-97F19FF0EAEE Q37622152-F4E1927E-985A-43A7-9D1E-D20938B104B7 Q37725761-8E89D5E5-864B-4902-905F-0C879587BC29 Q38704573-D9B42219-6C36-4C37-A15F-6C4FF3F356C5 Q38746598-75C5836D-E7A5-4DF4-B2A4-BDC3450C7E97 Q39043196-1E5AED08-91C3-43B8-BEA5-70F0242AA5FD Q40188258-72FF61A0-D39D-4123-8E48-554A449FED7F Q41894814-ECCCBD61-F927-4E9D-BE08-061C31BD9FA8 Q41939949-06C8602E-9BC7-47C2-9D6F-35B686412900 Q43196241-B0FDEFBA-B27A-4B18-8728-B2A9CE582F84 Q47113506-053EC878-5C71-46D0-8DF6-9414548E34AF Q50222492-453A5207-796E-45DA-A4AE-490B48A2360A Q51052882-66807B49-BA73-4508-8A2B-D4B4B5D86EA8 Q52733766-89A8E676-C7DE-4363-817B-BF303E669CE4 Q55235076-5B30AB31-AFC6-4F6C-B63A-DB2A109F48E4

P2860

High-avidity T cells are preferentially tolerized in the tumor microenvironment

http://www.wikidata.org/entity/Q34463820

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@ast

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@en

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@nl

type

label

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@ast

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@en

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@nl

prefLabel

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@ast

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@en

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@nl

P1433

Q34463820-ED12980C-34F4-4AE2-8436-1CC9FF6269DE

P1476

Q34463820-A7418768-9B8B-4264-B57A-2F33B7C62ADB

P2093

Q34463820-4EA8E1E4-C891-4633-8DE4-2DB0507F6C87

Q34463820-5549A6DE-E3FB-43DC-9ED6-D88F1886C2DA

Q34463820-6026E7FB-E0EC-4FD7-8AC4-0F1419EB3817

Q34463820-93576591-2958-402A-8F97-46EE02A621EE

Q34463820-A0E7B42E-D303-454E-BE4D-60189732022B

Q34463820-A889A88C-679D-466E-9B24-FA7C942BC558

Q34463820-ABCC536D-54D3-455E-A8F2-0DC48291069B

P2860

Q34463820-01928938-F9FC-4458-A418-E16219AB0137

Q34463820-01A54522-E918-42D0-89C7-76D0054E3E81

Q34463820-08428B1B-0BC0-48FA-8975-7D8ED781FC33

Q34463820-0C94F2E9-51DD-4F82-AE76-7C04768AC2F2

Q34463820-0F757D3C-6942-45DA-9BF6-A6F7AAAA6670

Q34463820-16452F66-983E-4AA8-AB21-F49AA47CB64C

Q34463820-16C68F6E-103A-4096-A681-6CAF24F35274

Q34463820-295AFC2D-0217-444A-B718-E044DCD9821C

Q34463820-2EE3CF9F-F98E-4A79-81D5-D35DCAFA4ECB

Q34463820-40241198-1A30-48D7-81FB-252AD4E05196

P304

Q34463820-80970A97-66E7-4598-BE10-0B1CDF1DFEAE

P31

Q34463820-491CE7A2-97F5-493F-BB9A-4992448AC613

P356

Q34463820-19118234-F9EF-444D-BE3C-B8C1223F741B

P407

Q34463820-07DE1AD8-12CC-41C0-8068-70364D908424

P433

Q34463820-32D87447-2C16-4127-9CD3-FF714E06F5A4

P478

Q34463820-2B140FA4-2B05-46B2-8CFD-DC422B3F503A

P577

Q34463820-377EC304-A8CD-4DFB-A6ED-622FC0B54164

P698

Q34463820-9C8630D3-F6D6-4ADB-A6FF-E363DB728D00

P932

Q34463820-A3764341-7EC5-43BA-822B-848BD5F94F83

P356

0008-5472.CAN-12-1123

P1433

Cancer Research

P1476

High-avidity T cells are preferentially tolerized in the tumor microenvironment

@en

P2093

Arthur A Hurwitz

http://www.w3.org/2001/XMLSchema#string

Jennifer L Shoe

http://www.w3.org/2001/XMLSchema#string

Lionel Feigenbaum

http://www.w3.org/2001/XMLSchema#string

Stephanie K Watkins

http://www.w3.org/2001/XMLSchema#string

Vincenzo Bronte

http://www.w3.org/2001/XMLSchema#string

Vinod Singh

http://www.w3.org/2001/XMLSchema#string

Ziqiang Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

PD-1 and its ligands in tolerance and immunity

Interferons, immunity and cancer immunoediting

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.

P304

595-604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-12-1123

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23204239

http://www.w3.org/2001/XMLSchema#string

P932

4222512

http://www.w3.org/2001/XMLSchema#string